Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
InChiKey: MXOOUCRHWJYCAL-UHFFFAOYSA-N
Pimecrolimus contrasts cyclosporine A and tacrolimus by inhibiting ongoing secondary inflammatory response
- A case series
[Epub ahead of print] PubMed PMID: 29233021
PubMed Central PMCID: PMC6711145
BS-181 14361 InChiKey: MXOOUCRHWJYCAL-UHFFFAOYSA-NNormal progression through the cell cycle requires the sequential action of cyclin dependent kinases (CDK1, CDK2, CDK4 and CDK6). Deregulation of CDK activity is a feature of almost all cancers and has led to the development of CDK inhibitors as anticancer agents. As such, CDK7 is an target for the anticancer drug development. Computer modeling of CDK7 was used to design potential potent CDK7 inhibitor, which is BS 181. Product information CAS Number: